Respiri Company Overview
Respiri
About Respiri
Respiri (ASX:RSH) is a medical technology company that develops and commercialises medical devices for the diagnosis and management of respiratory diseases. The company’s flagship product, wheezo®, a simple sensor and mobile app, empowers home monitoring of wheeze, a key indicator in asthma and other respiratory conditions. wheezo® detects abnormal breath sounds and translates them into a "WheezeRate," offering valuable data for both patients and their doctors for proactive management and timely interventions. Respiri aims to revolutionise chronic respiratory disease management by demystifying wheezing, driving informed treatment decisions, and ultimately improving respiratory health outcomes.
What is Respiri known for?
Snapshot
1987
Year founded
17
Employees
Melbourne, Australia
Head office
Loading Map...
Operations
All Locations
Melbourne, AU
Products and/or services of Respiri
- Access Telehealth: subsidiary of Respiri, is revolutionising chronic care management in the US with top-tier Remote Patient) solutions with its clinical team and software platform to facilitate remote care for patients with chronic illnesses.
- Wheezo: the pioneering FDA-approved Class II medical device by Respiri. It's the exclusive WheezeRate detector designed for seamless integration into RPM programs.
Respiri executive team
- Mr. Nicholas SmedleyExecutive Chairman
- Mr. Marjan Mikel B.Sc., M.A.I.C.D.CEO, MD & Executive Director
- Mr. Peter HildebrandtChief Operations Officer
- Mr. George VlachodimitropoulosChief Technology Officer
- Dr. Samaneh Sarraf ShiraziChief Research Officer
- Mr. Theo AntonopoulosChief Commercial Officer
- Mr. William SigsbeeHead of US Operations & Chief Commercial Officer for the US market
- Mr. Justin Mouchacca B.Bus (Acc), C.A., CAJoint Company Secretary
- Ms. Nova Anne TaylorJoint Company Secretary
- Prof. Noam GavrielyMedical & Scientific Advisor